Wizz Air says traffic declined in July after CrowdStrike outage
By Pierre Bertrand
Wizz Air Holdings reported a decline in both passenger numbers and seating capacity in July, when some of its flights were disrupted by the CrowdStrike outage that crashed computers around the world.
The eastern Europe-focused budget airline said it flew 5.9 million passengers last month, down 1.4% from 6.03 million in July of last year.
Wizz (UK:WIZZ) said around 1% of its flights were disrupted by last month's IT outage, which upended flight schedules across the globe.
On a rolling 12-month basis, passengers numbers rose nearly 12% to 62 million.
The airline's capacity edged down 0.3% on year in July to 6.3 million seats, but on a 12-month rolling basis was up nearly 12% higher at 68.9 million seats, the company said.
Load factor, a measure of how full planes are, declined to 93.8% in July from 94.9% a year ago, and was flat at 90% on a rolling 12-month basis.
Write to Pierre Bertrand at pierre.bertrand@wsj.com
This content was created by MarketWatch, which is operated by Dow Jones & Co. MarketWatch is published independently from Dow Jones Newswires and The Wall Street Journal.
(END) Dow Jones Newswires
08-02-24 0306ET
Copyright (c) 2024 Dow Jones & Company, Inc.-
What’s the Difference Between the CPI and PCE Indexes?
-
Micron Earnings: Great Guidance but Stock Now Looks Fairly Valued
-
August PCE Report Forecasts Show More Good News on Inflation
-
AI Stocks May Be Down, but Don’t Count Them Out
-
4 Stocks to Buy as the Fed Cuts Interest Rates
-
Markets Brief: The Uncertain Path to Neutral Interest Rates
-
What’s Happening in the Markets This Week
-
Where Top Stock Fund Managers Are Looking Next After the Fed Rate Cut
-
Our Top Pick for Investing in US Renewable Energy
-
How to Measure a Stock’s Uncertainty
-
How to Determine Whether a Stock Is Cheap, Expensive, or Fairly Valued
-
Why a Company’s Management and Capital Allocation Matter
-
How to Determine What a Stock Is Worth
-
How to Measure a Company’s Competitive Advantage
-
How to Think Like a Stock Analyst
-
How GLP-1 Drugs Like Ozempic Are Boosting Biopharma Stocks